Lin Gloria, Hein David M, Liu Po-Hong, Singal Amit G, Sanford Nina N
Departments of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Departments of Radiation Oncology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
Cancers (Basel). 2024 Mar 10;16(6):1110. doi: 10.3390/cancers16061110.
The effectiveness of colonoscopy to reduce colorectal cancer (CRC) mortality is extrapolated from cohort studies in the absence of randomized controlled trial (RCT) data, whereas flexible sigmoidoscopy is supported by RCT data and may be easier to implement in practice. We characterized the anatomic distribution of CRC to determine the proportion that is visible with sigmoidoscopy. Patients with a primary diagnosis of colorectal adenocarcinoma were identified in the Surveillance, Epidemiology, and End Results program (2000-2020). Tumors from the rectum to the descending colon were categorized as visible by sigmoidoscopy, whereas more proximal tumors required colonoscopy. Differential prognosis between tumor locations, stratified by age groups and stage, was assessed using the overall restricted mean survival time (RMST) at 2, 5, and 10 years. : Among 309,466 patients, 58% had tumors visible by sigmoidoscopy, including 73% of those under age 50 (OR 2.10, 95% CI 2.03-2.16 age < 45, OR 2.20, 95% CI 2.13-2.27 age 45-49 versus age ≥ 50). Male sex (OR 1.54, 95% CI 1.51-1.56) and Asian or Pacific Islander race (OR 1.60, 95% CI 1.56-1.64) were also positively associated with tumors visualizable by sigmoidoscopy. Across age groups, for local disease, RMST was comparable for tumors visible versus not visible on sigmoidoscopy. For regional and metastatic cancer, patients with tumors visible by sigmoidoscopy had improved RMST versus those with more proximal tumors. : 58% of CRC arises in locations visible by flexible sigmoidoscopy. Flexible sigmoidoscopy should be considered as a viable option for CRC screening, particularly in younger patients unwilling or unable to undergo colonoscopy.
在缺乏随机对照试验(RCT)数据的情况下,结肠镜检查降低结直肠癌(CRC)死亡率的有效性是从队列研究中推断出来的,而乙状结肠镜检查有RCT数据支持,并且在实践中可能更容易实施。我们对CRC的解剖分布进行了特征分析,以确定乙状结肠镜检查可见的比例。在监测、流行病学和最终结果计划(2000 - 2020年)中确定了原发性结直肠腺癌患者。从直肠到降结肠的肿瘤被分类为乙状结肠镜检查可见,而更靠近近端的肿瘤则需要结肠镜检查。使用2年、5年和10年的总体受限平均生存时间(RMST)评估按年龄组和分期分层的肿瘤位置之间的差异预后。在309466名患者中,58%的患者肿瘤乙状结肠镜检查可见,其中50岁以下患者中这一比例为73%(年龄<45岁时比值比[OR]为2.10,95%置信区间[CI]为2.03 - 2.16;年龄45 - 49岁时OR为2.20,95% CI为2.13 - 2.27,与年龄≥50岁相比)。男性(OR为1.54,95% CI为1.51 - 1.56)以及亚洲或太平洋岛民种族(OR为1.60,95% CI为1.56 - 1.64)也与乙状结肠镜检查可发现的肿瘤呈正相关。在各个年龄组中,对于局部疾病,乙状结肠镜检查可见与不可见的肿瘤的RMST相当。对于局部和转移性癌症,乙状结肠镜检查可见肿瘤的患者与肿瘤更靠近近端的患者相比,RMST有所改善。58%的CRC发生在乙状结肠镜检查可见的部位。应将乙状结肠镜检查视为CRC筛查的可行选择,特别是对于不愿意或无法接受结肠镜检查的年轻患者。